Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regenxbio

8.10
+0.64008.58%
Post-market: 8.140.0400+0.49%16:19 EDT
Volume:908.22K
Turnover:7.16M
Market Cap:409.17M
PE:-2.36
High:8.13
Open:7.56
Low:7.53
Close:7.46
52wk High:13.48
52wk Low:5.04
Shares:50.51M
Float Shares:41.40M
Volume Ratio:1.30
T/O Rate:2.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4333
EPS(LYR):-4.5871
ROE:-62.49%
ROA:-17.88%
PB:1.91
PE(LYR):-1.77

Loading ...

REGENXBIO Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jun 09

Raymond James Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
Jun 06

Crude Oil Moves Higher; Ciena Posts Downbeat Earnings

Benzinga
·
Jun 06

BUZZ-U.S. STOCKS ON THE MOVE-Texas Instruments, Broadcom, Circle

Reuters
·
Jun 06

BUZZ-U.S. STOCKS ON THE MOVE-PVH, Phio Pharma, Cracker Barrel

Reuters
·
Jun 05

Regenxbio’s RGX-202 shows efficacy in Phase 1/2 Duchenne trial

TIPRANKS
·
Jun 05

Regenxbio Inc. Announces Positive Interim Data from Phase I/II Trial of RGX-202 for Duchenne Muscular Dystrophy

Reuters
·
Jun 05

Regenxbio Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 04

Regenxbio Inc. to Release Interim Functional Data from Phase I/II AFFINITY DUCHENNE® Trial

Reuters
·
Jun 02

RegenXBio (RGNX) Receives a Buy from Leerink Partners

TIPRANKS
·
May 28

Regenxbio Signs Royalty Deal Worth Up to $250 Million With Healthcare Royalty

MT Newswires Live
·
May 20

BRIEF-Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million

Reuters
·
May 20

Regenxbio Secures Up to $250 Million Royalty Monetization Agreement with HCRx

Reuters
·
May 20

Regenxbio signs strategic royalty monetization agreement for up to $250M

TIPRANKS
·
May 20

Press Release: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

Dow Jones
·
May 20

Director Kenneth T. Mills Reports Disposal of Common Shares in Regenxbio Inc

Reuters
·
May 15

BRIEF-FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment

Reuters
·
May 14

Nippon Shinyaku Announces Strategic Partnership to Launch Investigational Gene Therapy RGX-121 for MPS II in U.S. and Asia

Reuters
·
May 14

Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review

MT Newswires Live
·
May 13

BRIEF-Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii

Reuters
·
May 13